Project 2 will validate a model of human-like TB latency in New Zealand White rabbits, and apply this model to test interventions against latent TB infections (LTBl). The world's latently infected population comprises the reservoir which feeds the global tuberculosis TB epidemic. Novel approaches to treat latent infections would contribute greatly to TB eradication. There is a critical need to develop an animal model that reflects the human spectrum of latency. The mouse is a poor model for LTBl; and our preliminary data and work by others suggests that latently-infected non-human primates are more likely percolators with significantly more bacterial replication and mutational stress than is seen with LTBl in humans. Rabbits infected with Mycobacterium tuberculosis (Mtb) strain CDC1551 develop a primary infection that is rapidly contained, after which the Mtb bacilli soon become undetectable in all rabbit tissues. Yet, like human latency, low numbers of Mtb bacilli persist in an undetectable (latent) state because they can be reactivated by immune suppression with corticosteroids. We will more fully study the range of bacterial activity that occurs in human latency at our clinical site in Vitoria, Brazil. These results will be used to benchmark, and if needed, fine tune (modify) our rabbit latency model. Next, we will use infections with a high-density bar-code Mtb library to measure (for the first time) the rate of Mtb cell killing during latency, the number of clones that survive during LTBl, and the replication and mutation rate during this disease state. We will then use high-density bar-coded Mtb to map the pathway of clonal re-emergence during reactivation. Mtb gene knockouts will be used to identify bacterial factors essential for latency LTBl. The rabbit latency model, bar-coded library and latency knockouts will then be used as tools to evaluate the efficacy of new therapeutic interventions in eradicating paucibacillary infection. Correlates of immunological protection identified in human TB in Project 1 will be queried in these efficacy studies. Cross-fertilizing with Project 4, we will establish the overlap between bacterial factors required for persistence vs. latency. The discovery of novel latency and persistence genes will identify new druggable targets active against the latent state.

Public Health Relevance

Tuberculosis hides within humans in a form called latency, only to remerge years to decades later and make people sick. How this happens is poorly understood. This proposal will develop new ways to kill latent tuberculosis which would contribute greatly to tuberculosis control and eventual eradication.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI111276-08
Application #
10004559
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2014-08-01
Project End
2021-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Rutgers University
Department
Type
DUNS #
078795851
City
Newark
State
NJ
Country
United States
Zip Code
07103
Vilchèze, Catherine; Kim, John; Jacobs Jr, William R (2018) Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice. Antimicrob Agents Chemother 62:
Acuña-Villaorduña, Carlos; Jones-López, Edward C; Fregona, Geisa et al. (2018) Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease. Eur Respir J 51:
Colangeli, Roberto; Jedrey, Hannah; Kim, Soyeon et al. (2018) Bacterial Factors That Predict Relapse after Tuberculosis Therapy. N Engl J Med 379:823-833
Ma, Y; Horsburgh, C R; White, L F et al. (2018) Quantifying TB transmission: a systematic review of reproduction number and serial interval estimates for tuberculosis. Epidemiol Infect 146:1478-1494
Vilchèze, Catherine; Copeland, Jacqueline; Keiser, Tracy L et al. (2018) Rational Design of Biosafety Level 2-Approved, Multidrug-Resistant Strains of Mycobacterium tuberculosis through Nutrient Auxotrophy. MBio 9:
Peloquin, Charles A; Phillips, Patrick P J; Mitnick, Carole D et al. (2018) Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. Antimicrob Agents Chemother 62:
Singhania, Akul; Verma, Raman; Graham, Christine M et al. (2018) A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection. Nat Commun 9:2308
Geadas, Carolina; Acuna-Villaorduna, Carlos; Mercier, Gustavo et al. (2018) FDG-PET/CT activity leads to the diagnosis of unsuspected TB: a retrospective study. BMC Res Notes 11:464
Esmail, Hanif; Lai, Rachel P; Lesosky, Maia et al. (2018) Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis. Proc Natl Acad Sci U S A 115:E964-E973
Jones-López, Edward C; Acuña-Villaorduña, Carlos; Fregona, Geisa et al. (2017) Incident Mycobacterium tuberculosis infection in household contacts of infectious tuberculosis patients in Brazil. BMC Infect Dis 17:576

Showing the most recent 10 out of 25 publications